Best case scenario now is that Silviu signs up a partnership and we can get some funding for our trials and also reduce the loans the company has taken. Worse case we sell our Priority review voucher and cash up the company for the upcoming trials. Sarepta sold its voucher 6 months ago for $US102m so we should be getting something around that figure. I think this announcement has completely changed the scenario for the company and I am confident we would be hearing some news soon in this regards. Good luck to all.
https://www.fiercepharma.com/pharma/sarepta-sells-prv-102m-mystery-buyer-another-example-declining-prices-fda-vouchers
Best case scenario now is that Silviu signs up a partnership and...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.030(2.55%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.12 | $5.905M | 5.167M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 33330 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 87817 | 6 |
View Market Depth
| Last trade - 11.15am 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
-0.030 ( 3.06 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.17 | $1.12 | 708027 | ||
| Last updated 11.33am 08/05/2024 ? | |||||
| MSB (ASX) Chart |